X
Thursday, May 22, 2025
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

American Scientist Federation Discusses AI Biosecurity Risks

Content Team by Content Team
18th December 2023
in News

The Federation of American Scientists- FAS has gone on to publish five policy recommendations so as to address the issues concerning AI when it comes to life sciences.

It is well to be noted that the Bio X AI policy recommendations point out the need for oversight in terms of biodesign AI tools, biosecurity screening of synthetic DNA, and guidance when it comes to biosecurity practices as far as automated laboratories are concerned.

FAS looks forward to the fact that these recommendations will aid in informing the policy development when it comes to these topics, which include the tasks of the National Security Commission on Emerging Biotechnologies.

According to the FAS, AI is most likely to make incredible advances in their fundamental understanding of biological systems and also have significant advantages for health, agriculture, along with the broader bioeconomy. But it is a fact that AI tools, if not used to their potential, misused, or created irresponsibly, can go on to pose risks in terms of biosecurity. The spectrum of biosecurity challenges concerning with AI happens to be complex and quickly changing, and gauging the issues needs some diverse aspects as well as expertise.

It is worth noting that significant effort has already been put into establishing frameworks so as to evaluate and lessen the risks from foundational AI models, such as large models that are put in place for varied purposes, like the recent Executive Order on Safe, Secure, as well as Trustworthy Development and the usage of AI. (Bioeconomy EO).

But specific regulations will be required to cover biodesign tools that are more specialized AI models trained when it comes to biological data and provide insight into biological systems.

The recommendations

  • Oliver Crook, who happens to be a postdoctoral researcher from the University of Oxford as well as a machine learning expert, has called upon the US government to make sure of responsible development when it comes to biodesign tools by having a framework in terms of checklist-based, institutional oversight in terms of these tools.
  • An AI-Biosecurity Fellow from the Centre for Long-Term Resilience, Richard Moulange, as well as Sophie Rose, the Centre for Long-Term Resilience’s Senior Biosecurity Policy Advisor, look to broaden the Executive Order when it comes to AI with recommendations for coming up with benchmarks so as to evaluate the risks.
  • Samuel Curtis, who happens to be an AI Governance Associate at The Future Society, goes on to take a more open-science approach, with a recommendation so as to expand infrastructure for cloud-based computational resources across borders so as to promote crucial advances in biodesign tools by way of establishing norms for a development that’s responsible in every way.
  • Scientist and biosecurity researcher Shrestha Rath goes on to focus on the biosecurity screening of synthetic DNA, which the Executive Order on AI underscores as a major safeguard, and has in it recommendations for how to enhance the screening methods to prepare better for designs produced by way of AI.
  • Biosecurity and bioweapons expert Tessa Alexanian go on to call for the US government to come up with guidance when it comes to biosecurity practices concerning automated laboratories, which are times also called cloud labs, that can create organisms as well as other biological agents.

FAS finally says that each of these recommendations goes on to present an opportunity for the US government so as to reduce risks concerning AI, make the position of the US as a global leader in AI governance more robust, and also make sure of a future that’s safer and more secure.

Previous Post

2024 May See Pharma, Life Sciences Have Sound M&A Activity

Next Post

First Ever List of Critical Medicines Published By Europe

Related Posts

Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
News

Types of Pharmaceutical Waste and How to Dispose of Them

31st December 2024
Developing Pharma Skills With Life Sci For Growth Initiative
News

UK Medicine Manufacturing Regulatory Framework For Care

6th November 2024
News

Nanoemulsion Drug Delivery Enhances Tuberculosis Care

6th November 2024
News

The Future of Drug Delivery Systems In Modern Medicine

6th November 2024
Revolutionizing Drug Discovery With AI For A Greener Future
News

AI and Nanotech Innovations in Advancing Drug Discovery

5th November 2024
Next Post

First Ever List of Critical Medicines Published By Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Notifications